NCT04462471View on ClinicalTrials.gov

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Thyroid CarcinomaThyroid CancerThyroid Cancer, FollicularThyroid Cancer (Follicular Cell)Thyroid Cancer, PapillaryBRAF V600E Mutation Positive
Interventions
DIAGNOSTIC_TEST

I-124 PET/CT lesion dosimetry

I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)

DRUG

Vemurafenib

Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid

DRUG

Copanlisib

Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer Center (All protocol activities), New York

10604

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | Biotech Hunter | Biotech Hunter